Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-JH040182 in FAP-Positive Malignancies
NCT07681141Phase 1Active, not recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 177Lu-JH040182 in malignancy, sponsored by The First Hospital of Fujian Medical University. Primary endpoint: Toxic and side effect at 50 months. Started Apr 2025; status: active, not recruiting.
02
Drugs
177Lu-JH040182
03
Conditions
malignancy
Beyond the preview
Go deeper on NCT07681141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07681141.